<DOC>
	<DOCNO>NCT01724580</DOCNO>
	<brief_summary>The Requesting Physician/Investigator contact Lilly , base medical opinion , patient meet criteria inclusion expand access program .</brief_summary>
	<brief_title>Compassionate Use Protocol Treatment Autoinflammatory Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Fever</mesh_term>
	<criteria>Are ≥17.5 month age . Participants young 17.5 month age consider enrollment discussion sponsor Have systemic sign symptom inflammation manifest presence two follow symptom : rash , fever , musculoskeletal pain , headache , fatigue , weakness , respiratory/breathing symptom , ulcers/ischemic lesion Have average daily Diary Score ≥0.5 ( CANDLE Diary ; use also CANDLErelated condition ) ≥1.0 ( SAVI JDM Diary ) assess least 2 week prior entry , available . Otherwise , participant complete diary study consent sign screen period meet inclusion criterion enrollment study Are ≥8.5 kilogram ( kg ) body weight . Participants weigh less 8.5 kg consider enrollment discussion sponsor Have previously treat least 1 biologic therapy , opinion investigator , respond longer respond therapy . If participant diagnose CANDLE , NakajoNishimura Syndrome ( NNS ) , SAVI , equivalent syndrome , need previous biologic therapy require Require treatment oral corticosteroid ( ≥0.15 milligram per kilogram per day [ mg/kg/d ] prednisone equivalent ) control systemic sign symptom chronic inflammatory disease least 2 week prior study entry , opinion investigator , fail adequate course steroid Have previous document elevation acutephase reactant ( example , high sensitivity Creactive protein ) consider result inflammatory disease ( patient CANDLE CANDLErelated condition ) Have ability provide inform consent legal representative willing able provide write informed consent , provide assent obtain participant ageappropriate level Have receive immunosuppressive biologic agent/monoclonal antibody within 4 halflives prior entry , example , anakinra ( 4 halflives=18 hour ) ; etanercept ( 4 halflives=18 day ) ; infliximab ; adalimumab ( 4 halflives=36 day ) ; use intravenous immune globulin ( IVIg ) permit Are pregnant nursing time entry Are females childbearing potential ( woman &gt; 12 least 1 menstrual period regardless age ) sexually active agree use 2 form highly effective method birth control remain abstinent study least 28 day follow last dose investigational product Are sexually active male agree use 2 form highly effective birth control female partner childbearing potential remain abstinent study least 28 day follow last dose investigational product Have symptomatic herpes zoster infection within 12 week prior entry screen period Have history disseminated/complicated herpes zoster ( example , multidermatomal involvement , ophthalmic zoster , central nervous system [ CNS ] involvement , postherpetic neuralgia ) Have evidence active infection , time entry screen period , opinion investigator , would pose unacceptable risk participate study Have history active hepatitis B ( HBV ) , hepatitis C ( HCV ) , human immunodeficiency virus ( HIV ) Have document high titer autoantibody suggestive clinically autoimmune disease severe JDM Are immunocompromised , opinion investigator , unacceptable risk participate study Have serious systemic local infection ( include infectious mononucleosislike illness herpes zoster ) within 12 week prior entry screen period Have expose live vaccine within 12 week prior entry expect need/receive live vaccine ( include herpes zoster vaccination ) course study . Note : Investigators review vaccination status participant follow local guideline vaccination nonlive vaccine intend prevent infectious disease prior enter participant study Have household contact person active tuberculosis ( TB ) receive appropriate document prophylaxis TB Have serious and/or unstable illness , opinion investigator , pose unacceptable risk participant 's participation study Have estimate glomerular filtration rate ( eGFR ) base recent available serum creatinine &lt; 40 milliliters/minute/1.73 per square meter Have history lymphoproliferative disease ; sign symptom suggestive possible lymphoproliferative disease , active primary recurrent malignant disease ; remission clinically significant malignancy &lt; 5 year Note : Participants resolve cervical dysplasia , 3 successfully treat basalcell carcinoma skin , may participate study Have history chronic alcohol abuse intravenous ( IV ) drug abuse within 2 year prior entry Are unable unwilling make available duration study and/or unwilling follow study restrictions/procedures Are currently enrol , discontinue within last 30 day clinical trial involve investigational product nonapproved use drug device ( investigational product use study ) , concurrently enrol type medical research judge scientifically medically compatible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>